Pertussis is an endemic disease in the EU/EEA and worldwide. Every three to five years, larger epidemics are expected even with high vaccination coverage.
In April 2019, Finland reported false-negative or equivocal results in patients tested for Chlamydia trachomatis (CT) using Aptima Combo 2 Assay (Hologic) (AC2).
This rapid risk assessment addresses the public health risk associated with the early occurrence of a large number of West Nile virus infections in the EU/EEA and EU neighbouring countries in 2018.
This document assesses the risk to human health posed by a multi-country foodborne outbreak of Shiga toxin-producing Escherichia coli (STEC) infections associated with haemolytic uraemic syndrome taking place in the European Union (EU).
This Rapid Risk Assessment focuses on acellular pertussis-containing combination vaccines used in national vaccination programmes in the EU/EEA Member States.
Early in 2015, a shortage of acellular pertussis-containing vaccines was brought to the attention of ECDC. This risk assessment provides a detailed list of mitigation options available to Member States.
The recent floods in Bosnia and Herzegovina, Croatia, and Serbia caused substantial damage. Following the floods, there is a risk of increased transmission of vector-borne infections to the populations.
West Nile virus (WNV) is an emerging pathogen whose ecology and epidemiology extend across multiple interfaces. As the epidemiology and transmission cycle of WNV is complex, assessing the risk of WNV being transmitted to humans is not always straightforward. Therefore, the WNV risk assessment tool has been developed to provide operational guidance in support of the risk assessment process.
Within the context of the West Nile virus outbreaks, an ECDC mission was conducted at the end of the transmission season to support the Greek authorities regarding further response and prevention activities on West Nile virus infections.
New and noteworthy in this update: the retrospective identification of novel coronavirus in biological samples from two fatal cases in Jordan (April 2012) and the results of a joint ECDC/WHO survey which confirms that EU/EEA Member States have an adequate capacity to detect novel coronavirus through their network of national reference laboratories: 18 of 30 in EU/EEA countries are capable of confirming positive screened samples by either ORF1b RT-PCR or other target RT-PCR assays with sequence analysis or whole-genome sequence analysis.